Korea Arlico Pharm알리코제약
260660 · KOSDAQ · ₩260660 · 알리코제약
- Market cap
- ₩30B
- Enterprise value
- ₩18B
- P/E
- —
- P/B
- 0.4×
- Dividend yield
- 3.8%
- ROE
- −3.8%
- Net margin
- −1.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−66.1% from the high
₩1,937Today: ₩1,937 – ₩1,995₩5,760
Returns
- 1W−8.5%
- 1M−16.5%
- 3M−10.6%
- 6M−46.7%
- YTD−54.4%
- 1Y−49.9%
- Volume today
- 29,228
- 1.6× the 20-day average
- Traded today
- ₩57M
- Listed shares
- 15,327,021
- EPS (12 months)
- −₩186
- Earnings yield −9.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 50 of 100 (50 is a normal day for this stock).
- MomentumWeak-14.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Korea Arlico Pharm stock overview
Korea Arlico Pharm (알리코제약, KRX: 260660) is listed on KOSDAQ, in the Biotech & Pharma sector. Alico Pharmaceutical is a South Korean pharmaceutical company founded in 1992 that manufactures and sells medicines. Its shares closed at ₩1,950 on Oct 28, 2026, down 2.01% on the day, giving it a market value of ₩30B.
Key facts
- Market cap
- ₩30B
- Sector
- Biotech & Pharma
- Latest price change
- −2.01%
- As of
- Oct 28, 2026
- Main business
- Alico Pharmaceutical is a South Korean pharmaceutical company founded in 1992 that manufactures and sells medicines.
Quick answers about Korea Arlico Pharm
- What does Korea Arlico Pharm do?
- Alico Pharmaceutical is a South Korean pharmaceutical company founded in 1992 that manufactures and sells medicines. Its main businesses include domestic sales of pharmaceuticals, contract manufacturing for other companies (CMO), export of medicines and trading products, medical devices, and health functional foods and cosmetics. Its key products include treatments for high cholesterol, cerebrovascular disease, gastrointestinal conditions, hypertension and allergy or respiratory conditions, and it operates production facilities in Chungbuk's Jincheon County.
- What is the market cap of Korea Arlico Pharm?
- The market capitalisation of Korea Arlico Pharm was ₩30B at the close on Oct 28, 2026.
- Who are the largest shareholders of Korea Arlico Pharm?
- According to the latest official filings, the largest reported holders are Lee Hang-gu (39.05%, as of Jun 4, 2026); Synergy IB Investment (7.41%, as of Aug 7, 2026); Lee Ji-hye (1.09%, as of May 26, 2026).
- When is the next earnings report from Korea Arlico Pharm?
- Korean companies rarely announce results dates in advance. Based on when Korea Arlico Pharm filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
Alico Pharmaceutical is a South Korean pharmaceutical company founded in 1992 that manufactures and sells medicines. Its main businesses include domestic sales of pharmaceuticals, contract manufacturing for other companies (CMO), export of medicines and trading products, medical devices, and health functional foods and cosmetics. Its key products include treatments for high cholesterol, cerebrovascular disease, gastrointestinal conditions, hypertension and allergy or respiratory conditions, and it operates production facilities in Chungbuk's Jincheon County.
Written by AI from the company's latest annual report.
- Korean name
- 알리코제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이항구 김대훈 (각자 대표이사)
- Founded
- Dec 1992
- Listed
- Feb 2018
- Listed shares
- 15,327,021
- Fiscal year ends
- Month 12
- Website
- www.arlico.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Insider shareholding reportOct 15, 2026
- Change of CEOSep 11, 2026
- [Attachment Added] Results of Extraordinary General Shareholders' MeetingSep 11, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 11, 2026
- Reference Document for Proxy Solicitation of Voting RightsAug 27, 2026
Titles in Korean until English translations are added.
Also known as: Korea Arlico Pharm / 알리코제약 / 260660 / KRX:260660
Source: KRX statistical information